You Should Know Something about 89396-94-1

From this literature《Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs)》,we know some information about this compound(89396-94-1)HPLC of Formula: 89396-94-1, but this is not all information, there are many literatures related to this compound(89396-94-1).

Heterocyclic compounds can be divided into two categories: alicyclic heterocycles and aromatic heterocycles. Compounds whose heterocycles in the molecular skeleton cannot reflect aromaticity are called alicyclic heterocyclic compounds. Compound: 89396-94-1, is researched, Molecular C20H28ClN3O6, about Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs), the main research direction is TA6366 blood pressure heart ACE pharmacol.HPLC of Formula: 89396-94-1.

The long-term oral administration of TA-6366 (I) (5 mg/kg/day) from 4-wk old impeded the genetic hypertension development with only a slight decrease in heart rate in spontaneously hypertensive rats (SHRs). However, the lower dose (1 mg/kg/day) of TA-6366 did not affect the development, but it lowered blood pressure after the development was almost accomplished. Concomitantly, relative heart weights in both the groups were markedly decreased to almost the same degree. The reduction of ACE activity in the aorta, brain and lung of both groups was found at 24 h after the final administration, particularly at the 5 mg/kg/day dose; and that of the aorta was kept at almost the same low level even on the 9th day of withdrawal. After withdrawal of TA-6366 (5 mg/kg/day), the decrease in blood pressure was sustained at least for 10 wk. The beneficial effect of TA-6366 on the hypertension development in SHRs seems to be related to its strong and long-lasting ACE inhibition, especially in the vasculature.

From this literature《Pharmacological studies on TA-6366, a new ACE inhibitor: II. Effect of long-term administration from the pre-hypertensive stage on blood pressure, relative heart weight and ACE activity of various tissues in spontaneously hypertensive rats (SHRs)》,we know some information about this compound(89396-94-1)HPLC of Formula: 89396-94-1, but this is not all information, there are many literatures related to this compound(89396-94-1).

Reference:
Copper catalysis in organic synthesis – NCBI,
Special Issue “Fundamentals and Applications of Copper-Based Catalysts”